Lynparza first PARP drug to show promise in breast cancer
AstraZeneca has been boosted by results from ASCO which show its Lynparza could expand its use beyond ovarian cancer.
Results from a phase 3 trial presented today showed that patients treated with Lynparza (olaparib) had a 42% reduction in risk of their disease worsening or death in for patients with HER2-negative gBRCA-mutated metastatic breast cancer.
The OlympiAD trial showed median risk of disease worsening or death was 7.0 versus 4.2 months compared to those who received chemotherapy (capecitabine, vinorelbine, eribulin).
This makes Lynparza the first in the PARP inhibitor class of drugs to show efficacy in breast cancer, and the data paves the way for AstraZeneca to file the drug with regulators in this use.
The trial was named among the “Best of ASCO” selection, underlining its significance in this group of patients.
Mark E. Robson, Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, New York and Principal Investigator of OlympiAD said, “The OlympiAD data presented today demonstrate the benefit of olaparib in delaying the progression of advanced BRCA-mutated breast cancer. With few alternatives available, a targeted non-chemotherapy oral treatment in this setting could be a beneficial new option for patients.”
[caption id="attachment_28515" align="alignnone" width="320"]
Sean Bohen[/caption]
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said, “The OlympiAD results shared today mark the first time a targeted therapy shows benefit over the current standard of care for patients with HER2-negative gBRCA-mutated metastatic breast cancer. This also represents an important milestone for Lynparza as this is the first positive phase 3 trial in which a PARP inhibitor has shown a significant benefit for patients outside of ovarian cancer.”
AstraZeneca’s closest rival is Tesaro, which has its own PARP inhibitor, Zejula (niraparib) competing with Lynparza in ovarian cancer since its US launch in late April.
Tesaro has advantages over Lynparza as it is the only drug in the class to show efficacy in patients without mutations in a randomised phase 3 trial and doesn’t require patient selection with a biomarker test.
Tesarao showcased its phase 1/2 clinical trial TOPACIO which combined niraparib with immunotherapy Keytruda in patients with recurrent, platinum-resistant ovarian cancer or triple negative breast cancer. These early results showed a disease control rate of 69% observed (9 of 13 evaluable patients), including three partial responses and one complete response, while the most common grade ≥3 adverse events included thrombocytopenia, anaemia and neutropenia.
Also competing in the same therapy area with a PARP inhibitor is Clovis Oncology and its Rubraca (rucaparib),though it is anticipated to trail Tesaro and AZ in the market. Top line results from its ARIEL3 in ovarian cancer are anticipated by the end of June, and the company is also investigating its drug in breast cancer and prostate cancer.
For AstraZeneca, success in oncology is vital to its plans for future growth, though Lynparza isn’t as significant as its immunotherapy Imfinzi and lung cancer drug Tagrisso.
